December 28, 2017 / 12:36 PM / 7 months ago

BRIEF-Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018

Dec 28 (Reuters) - Intercept Pharmaceuticals Inc:

* INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING Source text: (bit.ly/2CgH2Og) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below